The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade
Abstract
OBJECTIVE: To evaluate change in mean clinic HbA1c from 2014 to 2021 with diabetes technology use in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this single-center study, we analyzed diabetes technology use and mean clinic HbA1c among unique adults (age ≥18 years) with type 1 diabetes (last visit of the year per patient) between 1 January 2014 and 31 December 2021 from the electronic medical record. Diabetes technology use was defined as the use of continuous glucose monitors (CGMs) without an automated insulin delivery (AID) system or an AID system. Diabetes technology use and HbA1c over time were analyzed using mixed models adjusted for age, sex, and visit year. RESULTS: A total of 15,903 clinic visits over 8 years (mean 1,988 patients per year, 4,174 unique patients, 52.7% female, 80.0% Non-Hispanic White) showed significant increases in CGM and AID use (P < 0.001 for both), resulting in an increase of diabetes technology use from 26.9% in 2014 to 82.7% in 2021. These increases were associated with a lower mean clinic HbA1c (7.7–7.5%, P < 0.001) and a higher percentage of adults achieving an HbA1c <7.0% (32.3–41.7%, P < 0.001) from 2014 to 2021. The HbA1c difference between technology users and nonusers increased over time from 0.36% (95% CI 0.26–0.47%, P < 0.001) in 2014 to 0.93% (95% CI 0.80–1.06%, P < 0.001) in 2021. CONCLUSIONS: Adopting diabetes technology in adults with type 1 diabetes decreased HbA1c and increased the number of people achieving an HbA1c <7.0%, supporting the current international recommendation to offer AID systems to most individuals with type 1 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, use of diabetes technology overall improves A1C and increases the number of people achieving an A1C <7% (14).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [14]
Citations
Cites
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Bulletin of the World Health Organization · doi:10.2471/blt.07.045120 · Cited by 1,632
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Heinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Self-citationAleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329
Self-citation7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
Brown, S. A., Forlenza, G. P., Bode, B. W., Pinsker, J. E., Levy, C. J., Criego, A. B., Hansen, D. W., Hirsch, I. B., Carlson, A. L., Bergenstal, R. M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0172 · Cited by 286
Self-citationCollyns, O. J., Meier, R. A., Betts, Z. L., Chan, D. S. H., Frampton, C., Frewen, C. M., Hewapathirana, N. M., Jones, S. D., Roy, A., Grosman, B., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2250 · Cited by 276
Multicenter, randomized trial of a bionic pancreas in type 1 diabetes
Bionic Pancreas Research Group (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2205225 · Cited by 216
Messer, L. H., Berget, C., Vigers, T., Pyle, L., Geno, C., Wadwa, R. P., Driscoll, K. A., & Forlenza, G. P. (2020) · Pediatric Diabetes · doi:10.1111/pedi.12971 · Cited by 161
Boughton, C. K., Hartnell, S., Thabit, H., Mubita, W. M., Draxlbauer, K., Poettler, T., Wilinska, M. E., Hood, K. K., Mader, J. K., Narendran, P., et al. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00005-8 · Cited by 127
Lipman, T. H., & Hawkes, C. P. (2020) · Diabetes Care · doi:10.2337/dci20-0048 · Cited by 103
Aktürk, H. K., Agarwal, S., Hoffecker, L., & Shah, V. N. (2021) · Diabetes Care · doi:10.2337/dc20-3063 · Cited by 81
Self-citationChampakanath, A., Akturk, H. K., Alonso, G. T., Snell-Bergeon, J. K., & Shah, V. N. (2022) · Diabetes Care · doi:10.2337/dc21-2004 · Cited by 76
Self-citationWelsh, J. B., Gao, P., Derdzinski, M., Puhr, S., Johnson, T. K., Walker, T. C., & Graham, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0374 · Cited by 72
Mulinacci, G., Alonso, G. T., Snell-Bergeon, J. K., & Shah, V. N. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0257 · Cited by 66
Self-citationBerget, C., Aktürk, H. K., Messer, L. H., Vigers, T., Pyle, L. L., Snell‐Bergeon, J. K., Driscoll, K. A., & Forlenza, G. P. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14441 · Cited by 49
Self-citationComparisons of Fifth-, Sixth-, and Seventh-Generation Continuous Glucose Monitoring Systems
Welsh, J. B., Psavko, S., Zhang, X., Gao, P., & Balo, A. K. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221099879 · Cited by 46
Welsh, J. B., Zhang, X., Puhr, S., Johnson, T. K., Walker, T. C., Balo, A. K., & Price, D. A. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818798816 · Cited by 35
Ebekozien (2020) · Journal of clinical outcomes management · doi:10.12788/jcom.0031 · Cited by 30
Factors Associated With Improved A1C Among Adults With Type 1 Diabetes in the United States
Aktürk, H. K., Rompicherla, S., Rioles, N. A., Desimone, M. E., Weinstock, R. S., Haw, S. J., Ziemer, D. C., Dickinson, J. K., Agarwal, S., Ebekozien, O. A., et al. (2022) · Clinical Diabetes · doi:10.2337/cd22-0067 · Cited by 29
Nguyen, A., & White, J. R. (2022) · Clinical Diabetes · doi:10.2337/cd22-0102 · Cited by 29
FDA approves first automated insulin delivery device for type 1 diabetes
(2016) · Case Medical Research · doi:10.31525/cmr-29dcfd7 · Cited by 9
Cited by
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
7. Diabetes Technology: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s007 · Cited by 281
Semaglutide in Adults with Type 1 Diabetes and Obesity
Shah, V. N., Akturk, H. K., Kruger, D., Ahmann, A., Bhargava, A., Bakoyannis, G., Pyle, L., & Snell-Bergeon, J. K. (2025) · NEJM Evidence · doi:10.1056/evidoa2500173 · Cited by 62
Self-citationEffectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes
Snell-Bergeon, J. K., Kaur, G., Renner, D., Akturk, H. K., Beatson, C., & Garg, S. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0328 · Cited by 40
“32 Most of the patients in this study did not reach the 1 or 2 mg dose of semaglutide or the 15 mg dose of tirzepatide as recommended for patients with T2D.”
Self-citationShah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
“3,103,104 The difficulty with attaining more targeted glycemia is multifactorial; however, two factors are likely most instrumental with this struggle.”
Self-citation
Metadata
- Authors
- Karakus, K. E., Akturk, H. K., Alonso, G. T., Snell-Bergeon, J. K., & Shah, V. N.
- Affiliations
- Koç University (TR)
- 1Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO
- University of Colorado Anschutz (US)
- Corresponding author
- Shah, Viral N.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-07-17
- Volume
- 46
- Issue
- 9
- Pages
- 1646-1651
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4384560404
- Cited by
- 52
- References
- 28
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 24
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, diabetes technology, continuous glucose monitoring, artificial pancreas, glycemic control, HbA1c, adults, technology adoption trends, glycemic targets
- MeSH terms
- Adolescent, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Blood Glucose Self-Monitoring, Pancreas, Artificial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.